285 related articles for article (PubMed ID: 12559279)
1. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses.
Lotan Y; Roehrborn CG
Urology; 2003 Jan; 61(1):109-18; discussion 118. PubMed ID: 12559279
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa.
Zein T; Wajsman Z; Englander LS; Gamarra M; Lopez C; Huben RP; Pontes JE
J Urol; 1984 Oct; 132(4):670-1. PubMed ID: 6471209
[TBL] [Abstract][Full Text] [Related]
3. Urine cytology in bladder tumors.
Zein TA; Milad MF
Int Surg; 1991; 76(1):52-4. PubMed ID: 2045253
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
Lotan Y; Roehrborn CG
J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
[TBL] [Abstract][Full Text] [Related]
7. [Non-invasive urinary diagnosis of bladder cancer. What do we know?].
Kausch I; Böhle A
Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034
[TBL] [Abstract][Full Text] [Related]
8. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
[TBL] [Abstract][Full Text] [Related]
9. Multiple mucosal biopsies and postoperative urinary cytology in patients with bladder cancer.
Gil-Salom M; Sánchez MC; Chuan P; Clar F; Santamaría J; García-Sisamón F
Eur Urol; 1990; 17(4):281-5. PubMed ID: 2364965
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
Stampfer DS; Carpinito GA; Rodriguez-Villanueva J; Willsey LW; Dinney CP; Grossman HB; Fritsche HA; McDougal WS
J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
Konety BR; Metro MJ; Melham MF; Salup RR
Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
15. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
16. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
17. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
18. [Tumor markers for bladder cancer: up-to-date study by the Kiel Tumor Bank].
Hautmann S; Eggers J; Meyhoff H; Melchior D; Munk A; Hamann M; Naumann M; Braun PM; Jünemann KP
Urologe A; 2007 Nov; 46(11):1508-13. PubMed ID: 17932643
[TBL] [Abstract][Full Text] [Related]
19. [Urinary cytology in cases of bladder cancer: a critical evaluation].
Rathert P
Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of stage O, grade I bladder cancer by cytology alone--is it acceptable?
Morrison DA; Murphy WM; Ford KS; Soloway MS
J Urol; 1984 Oct; 132(4):672-4. PubMed ID: 6471210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]